Protein test to tell pancreatic and bile duct cancers apart
Part of Cancer clinical trials.
This trial uses a protein test to help tell the difference between pancreatic cancer and bile duct cancer. It may help doctors choose the right treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had surgery (pancreaticoduodenectomy, also called Whipple procedure) for pancreatic cancer or bile duct cancer.
- You did not receive chemotherapy before your surgery.
- You agree to let the researchers use your data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing if a new protein-based lab test can better identify bile duct cancer from stored tissue samples. It's looking for people who had a bile duct sample taken but don't yet have a clear cancer diagnosis.
This trial tests whether a sample of bile (a fluid produced by your liver) can help doctors diagnose bile duct cancer more accurately. If you have a narrowing in your bile duct and need a procedure to take a tissue sample, you may be able to participate.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.